Spexis AG/ CH0106213793 /
- - | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
-USD | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | 5.5 mill.USD | - | - |
GlobeNewswire
25/04
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of ...
GlobeNewswire
09/04
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire
13/02
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire
29/09/2023
Spexis provides business update and announces financial results for the first half of 2023
GlobeNewswire
28/09/2023
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
GlobeNewswire
15/08/2023
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studie...
GlobeNewswire
28/06/2021
Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced ...
GlobeNewswire
08/06/2021
Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe ...
GlobeNewswire
01/06/2021
Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activi...
GlobeNewswire
05/01/2021
Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Ann...
GlobeNewswire
22/12/2020
Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin
GlobeNewswire
14/12/2020
Polyphor Announces Third Positive Data Safety Monitoring Board (DSMB) Recommendation to Continue Pha...
GlobeNewswire
11/12/2020
Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing Development of ...
GlobeNewswire
24/11/2020
Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinica...
GlobeNewswire
29/10/2020
Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer